Also listed under Neuroendocrine Tumors, Skin Neoplasms
71 trials changed in the last 30 days: 4 stopped, 30 with notable changes, 37 with minor changes only.
Trial terminated
Also in this update: Primary completion date changed from estimate of Feb 2028 to Apr 27, 2026
Agenus Inc.Phase 2 NCT05529316 Registry history of NCT05529316 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Study completion date changed from estimate of Jul 2028 to Jun 19, 2026; Final enrollment: 5 participants (planned 40)
Iovance Biotherapeutics, Inc.Phase 1 NCT06566092 Registry history of NCT06566092 on ClinicalTrials.gov (opens the registry)
Trial status changed: Recruiting → Withdrawn
Also in this update: Study completion moved earlier from Aug 2030 to Oct 2026; Primary completion moved earlier from Aug 2027 to Oct 2026
University of UtahPhase 2 NCT06365619 Registry history of NCT06365619 on ClinicalTrials.gov (opens the registry)
Recruitment suspended
Washington University School of MedicinePhase 1 NCT05629546 Registry history of NCT05629546 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Oct 30, 2026 to Jun 25, 2027
Also in this update: Study completion pushed from Oct 31, 2026 to Jun 25, 2027
Novartis PharmaceuticalsPhase 1 NCT03891953 Registry history of NCT03891953 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2025 to Dec 31, 2027
Also in this update: Study completion pushed from Dec 30, 2026 to Dec 31, 2027
Shandong Boan Biotechnology Co., LtdPhase 1 NCT06596915 Registry history of NCT06596915 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jan 31, 2027 to Aug 2, 2027
National Cancer Institute (NCI)Phase 1/2 NCT05896839 Registry history of NCT05896839 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 30, 2026 to Jan 30, 2028
Also in this update: Study completion pushed from Jan 30, 2026 to Jan 30, 2030
Melanoma and Skin Cancer Trials LimitedPhase 1/2 NCT06163820 Registry history of NCT06163820 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 1, 2026 to Jul 1, 2027
Mohamed Abdel-RahmanNot specified NCT04792463 Registry history of NCT04792463 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027
National Cancer Institute (NCI)Phase 2 NCT02465060 Registry history of NCT02465060 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 1, 2024 to Nov 13, 2025
Also in this update: Final enrollment: 86 participants (planned 63)
Abramson Cancer Center at Penn MedicinePhase 2 NCT03757689 Registry history of NCT03757689 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028
M.D. Anderson Cancer CenterPhase 1/2 NCT00508443 Registry history of NCT00508443 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 18, 2025 to Jul 30, 2026
Also in this update: Study completion moved earlier from Dec 18, 2027 to May 12, 2027
Abramson Cancer Center at Penn MedicineEarly Phase 1 NCT05279027 Registry history of NCT05279027 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Enrollment closed, study ongoing; Interventions modified
Aura BiosciencesNot specified NCT07421739 Registry history of NCT07421739 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jun 2027 to Jun 2028
Also in this update: Enrollment increased: 500 → 800 participants
University Health Network, TorontoNot specified NCT05196087 Registry history of NCT05196087 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 6, 2026 to Jul 6, 2027
University Health Network, TorontoNot specified NCT03702309 Registry history of NCT03702309 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified
University Health Network, TorontoPhase 2 NCT07820033 Registry history of NCT07820033 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Completed without a posted recruiting period; Primary completion date changed from estimate of Apr 2026 to Sep 26, 2025
Sona Nanotech IncNot applicable NCT06894407 Registry history of NCT06894407 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Sponsor changed: Eastern Cooperative Oncology Group to ECOG-ACRIN Cancer Research Group; Recruitment opened
ECOG-ACRIN Cancer Research GroupPhase 3 NCT07068074 Registry history of NCT07068074 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Sponsor changed: Dana-Farber Cancer Institute to Brigham and Women's Hospital; Results posted: Sep 29, 2026
Brigham and Women's HospitalNot applicable NCT03075072 Registry history of NCT03075072 on ClinicalTrials.gov (opens the registry)
Trial status changed: Enrolling by Invitation → Completed
Also in this update: Primary completion date changed from estimate of May 30, 2026 to Feb 20, 2026; Final enrollment: 5 participants (planned 10)
Hangzhou Huasai Biomedicine Co., Ltd.Phase 1 NCT06941818 Registry history of NCT06941818 on ClinicalTrials.gov (opens the registry)
Trial completed
Toray Industries, IncPhase 1 NCT03872947 Registry history of NCT03872947 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 22 participants (planned 30)
Phio Pharmaceuticals Inc.Phase 1 NCT06014086 Registry history of NCT06014086 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Oct 1, 2026 to Sep 1, 2026; Final enrollment: 1334 participants (planned 1020)
Dana-Farber Cancer InstituteNot applicable NCT05225428 Registry history of NCT05225428 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 30, 2026 to Nov 30, 2026
Also in this update: Enrollment increased: 115 → 160 participants; Study completion pushed from Dec 30, 2026 to Dec 30, 2028
Medicenna Therapeutics, Inc.Phase 1/2 NCT05086692 Registry history of NCT05086692 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 2026 to May 26, 2026
ECOG-ACRIN Cancer Research GroupPhase 3 NCT00003641 Registry history of NCT00003641 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 2027 to Mar 31, 2028
Toray Industries, IncPhase 1/2 NCT05423262 Registry history of NCT05423262 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Jun 30, 2026 to Apr 9, 2025
Emory UniversityPhase 2 NCT03719131 Registry history of NCT03719131 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion pushed from Jun 2026 to Dec 2026
Monash UniversityNot specified NCT05180942 Registry history of NCT05180942 on ClinicalTrials.gov (opens the registry)
Trial status changed: Recruiting → Not Yet Recruiting
Institute of Oncology LjubljanaNot applicable NCT07761871 Registry history of NCT07761871 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 2027 to Dec 2027
University of Michigan Rogel Cancer CenterNot applicable NCT07529080 Registry history of NCT07529080 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 2026 to Dec 2026
Melanoma Institute AustraliaPhase 2 NCT03340129 Registry history of NCT03340129 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 208 → 254 participants
Obsidian Therapeutics, Inc.Phase 1/2 NCT06060613 Registry history of NCT06060613 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 66 → 53 locations
Aura BiosciencesPhase 3 NCT06007690 Registry history of NCT06007690 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2026 to May 1, 2027
Mayo ClinicPhase 2 NCT06265285 Registry history of NCT06265285 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 18, 2026 to May 15, 2027
Mayo ClinicPhase 2 NCT07285044 Registry history of NCT07285044 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 13 → 16 locations
Perspective TherapeuticsPhase 1/2 NCT05655312 Registry history of NCT05655312 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 107 → 127 locations
Eikon TherapeuticsPhase 2/3 NCT06697301 Registry history of NCT06697301 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 91 → 94 locations
Daiichi SankyoPhase 2 NCT06172478 Registry history of NCT06172478 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 12 → 22 locations
Pliant Therapeutics, Inc.Phase 1 NCT06270706 Registry history of NCT06270706 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 15 → 20 locations
PfizerPhase 1 NCT07519655 Registry history of NCT07519655 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 2 → 47 locations
Paradigm HealthNot specified NCT06605404 Registry history of NCT06605404 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 118 → 173 participants
University of Southern CaliforniaNot specified NCT07259304 Registry history of NCT07259304 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 467 → 486 locations
Wake Forest University Health SciencesNot specified NCT06418204 Registry history of NCT06418204 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Sep 19, 2026 to Sep 17, 2027
National Cancer Institute (NCI)Phase 1 NCT03816332 Registry history of NCT03816332 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 2, 2026 to Sep 1, 2027
City of Hope Medical CenterPhase 1 NCT02432963 Registry history of NCT02432963 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Jul 14, 2027 to Nov 25, 2026
Boehringer IngelheimPhase 1 NCT05068102 Registry history of NCT05068102 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Dec 23, 2026 to Apr 15, 2026
USWM CT, LLCPhase 1 NCT04044859 Registry history of NCT04044859 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 2026 to Oct 2026
University of Wisconsin, MadisonPhase 1/2 NCT07281924 Registry history of NCT07281924 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Feb 2030 to Jul 2027
Also in this update: Primary completion moved earlier from Feb 2028 to Jul 2027
Providence Health & ServicesPhase 2 NCT05913388 Registry history of NCT05913388 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Nov 13, 2026 to Jul 30, 2026
Ravi Amaravadi, MDPhase 1/2 NCT04464759 Registry history of NCT04464759 on ClinicalTrials.gov (opens the registry)
Interventions modified
Washington University School of MedicinePhase 1 NCT06529822 Registry history of NCT06529822 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
ENB Therapeutics, IncPhase 1/2 NCT04205227 Registry history of NCT04205227 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Recruiting
N.N. Petrov National Medical Research Center of OncologyPhase 2 NCT06229340 Registry history of NCT06229340 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
University Hospital TuebingenNot specified NCT06680323 Registry history of NCT06680323 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Centre Hospitalier Universitaire de BesanconNot specified NCT06586593 Registry history of NCT06586593 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCSNot specified NCT05878964 Registry history of NCT05878964 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-13 | NCT07870265 Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System | Masaryk Memorial Cancer Institute new | |
| 2026-10-06 | NCT07861022 Biomechanical Characterization of Skin Properties Using Impact Based-Analysis Method… | Centre Hospitalier Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris new | |
| 2026-10-05 | NCT07857616 SI-B036-ST-101 in Advanced/Metastatic Solid Tumors | SystImmune Inc. new | Phase 1 |
| 2026-09-25 | NCT07841925 A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other… | Sichuan Baili Pharmaceutical Co., Ltd. new | Phase 1/2 |
| 2026-09-21 | NCT07831083 Skin Cancer Among Outdoor Workers | Assuta Medical Center new | |
| 2026-09-08 | NCT07808164 ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study… | Tam Anh Research Institute new | |
| 2026-08-12 | NCT07760012 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors | Peking University Third Hospital new | |
| 2026-08-05 | NCT07747935 Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma | ReBio Pharma new | Phase 1/2 |
| Early Phase 1 | 16 | |
| Phase 1 | 152 | |
| Phase 1/2 | 125 | |
| Phase 2 | 200 | |
| Phase 2/3 | 11 | |
| Phase 3 | 52 | |
| Phase 4 | 9 |
M.D. Anderson Cancer Center (44) · National Cancer Institute (NCI) (39) · Memorial Sloan Kettering Cancer Center (19) · University Health Network, Toronto (14) · H. Lee Moffitt Cancer Center and Research Institute (13) · Bristol-Myers Squibb (9) · Mayo Clinic (9) · Melanoma Institute Australia (9) · Institute of Oncology Ljubljana (8) · Vastra Gotaland Region (8)